期刊
BRITISH JOURNAL OF CANCER
卷 100, 期 3, 页码 431-435出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604891
关键词
melanoma; targeted therapy; BRAF; PI3K; mTOR; PTEN; chemotherapy
类别
The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据